MarketWatch

Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist ...

The MarketWatch News Department was not involved in the creation of this content. Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of ...
Business Wire

Tris Pharma Reports Positive Clinical Results of Intranasal Human Abuse Potential Study Indicating Low Abusability of Cebranopadol, an Investigational, First-in-Class Oral Dual ...

– Study met primary endpoint demonstrating cebranopadol is significantly less abusable than oxycodone when taken intranasally (i.e., snorted) with majority of patients indicating no desire to take ...
Business Wire

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical ...